Market Cap$11.38B
P/E62.58x
PEG Ratio2.11
Div yield0.50%
Beta1.28
TECH Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)13.81%
Price vs S&P 500 (4W)1.46%
PEG Ratio2.11
VGM Score51.64
P/E Ratio (Annual)62.58x
Indicated Dividend Yield (Annual)0.50%
TECH Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.52 | $0.52 | +0.13%(+$0.00) | |
| Q1 2026 | $0.53 | $0.53 | -0.82%(-$0.00) | |
| Q4 2025 | $0.43 | $0.46 | +5.84%(+$0.03) | |
| Q3 2025 | $0.42 | $0.42 | -0.36%(-$0.00) | |
| Q2 2025 | $0.50 | $0.53 | +5.79%(+$0.03) |
TECH Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
3.57
3.55
3.45
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
TECHBio-Techne Corp. | D | C | B | 9.4x | -0.4% | 66.2% | 6.0% | $72.57 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Bio-Techne Corp.
Bio-Techne is a life sciences manufacturer providing consumables and instruments to pharmaceutical, biotech, academic, and diagnostic markets through two segments: protein sciences (75% of revenue), supplying reagents and analytical instruments including antibodies for protein analysis, and diagnostics and genomics (25%), offering diagnostic reagents, molecular diagnostics, and spatial biology products. The company generates approximately 55% of revenue from the United States, with the remainder from Europe, Asia-Pacific, and other international markets. This diversified product portfolio and geographic footprint position the company to serve multiple end-markets within the life sciences research and diagnostic sectors.